Group Leader （分子生物学 & 酵母遗传）
天演药业（苏州）有限公司
- 公司规模：少于50人
- 公司性质：外资(欧美)
- 公司行业：制药/生物工程 医疗/护理/卫生
职位信息
- 发布日期：2014-05-29
- 工作地点：苏州-工业园区
- 招聘人数：1
- 工作经验：一年以上
- 学历要求：博士
- 语言要求：英语熟练
- 职位月薪：面议
- 职位类别：生物工程/生物制药
职位描述
任职要求：
1、生物或医学相关专业，博士学历或硕士学历5年以上工作经验；
2、 有较强的分子生物学及酵母遗传学研究背景，在国际刊物发表过高水平论文；
3、具备优秀的英文文献阅读和科研思维能力，有很强的解决问题能力；
4、 具有较好的与人沟通交流能力，较强的学习能力，具有团队精神与协作能力。
备注： 1）此职位工作地点江苏省苏州市
2）简历要求：word/PDF文档，中英文
公司名称：天演药业（苏州）有限公司
公司地址：江苏省苏州市工业园区星湖街218号生物纳米园C14栋4楼
招聘邮箱：hr2013@adagene.com
联系人: 陈女士 0512-87773615
公司介绍
天演药业是一家致力于开发原创性抗体技术的生物制药公司。 公司将先进的信息技术和生物技术相结合，突破现有抗体技术在免疫应答方面的局限性，开发出原创性的智能化抗体技术--准确、快速、有效地控制靶向人源化抗体的生成、优化及表达。
天演药业由享誉全球的风险投资家、创业家、科学家、工程师及资深科学，法律及商业顾问组成。公司是由两位成功的生物医药企业家携手创办：创始人兼总裁罗培志博士曾任美国默克全资子公司抗体优化公司(Abmaxis)的共同创始人及首席技术官，兼默克公司(Merck & CO)生物制药研发部门主任；共同创始人李革博士是纽约上市公司--药明康德新药开发有限公司 (Wuxi AppTec)的创始人、董事长兼总裁。 天演药业由全球最大的投资管理集团富达风险基金─美国富达生物科技(Fidelity Bioscience)、富达国际风险投资(Fidelity Growth Partners Asia)和药明康德风险基金（Wuxi AppTec Venture）共同投资。
公司核心团队深厚的基础研究功底，精益求精的工作态度和强烈的创新意识，为技术和产品原创性提供根本的保证。 创业团队丰富的第一手实践经验及锐意进取的创业精神为公司的成长提供持续不断的动力。
天演药业将以其核心技术为动力，推动上游和下游的抗体技术之间的无缝整合， 为快速增长的治疗及诊断用抗体市场提供优质的产品及技术服务。 公司将开发针对恶性肿瘤的靶向治疗及诊断用抗体，并进一步扩展至针对重大疾病的抗体产品线。
公司简介（英）：
Adagene is an emerging biopharmaceutical company focused on developing novel technology based on computational biology and genetic engineering for generation and engineering of premier antibodies tailored to diagnostic and therapeutic application. The unique combination of the cutting edge informational technology and biotechnology for antibody engineering has positioned Adagene in the very front of the next generation of antibody technology for unmet biomedical needs in research, diagnostic and therapeutic applications. We are looking for self-motivated, ambitious engineers and scientists with solid training in IT and BT to develop your careers with us in a dynamic and fast-paced startup company.
Adagene is founded by two successful entrepreneurs in biopharmaceutical industry, Dr. Peter PeizhiLuo, Chairman and CEO of Adagene, who was the former director of biologics at Merck & Co., and Cofounder & Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co;and Dr. Ge Li, the founder, Chairman and CEO of WuXiAppTec Co., Ltd., a NYSE-listed global biopharmaceutical company. Adagene is backed by leading life science investors in US and Asia: Fidelity Bioscience in Boston, Fidelity Growth Fund, and Wuxi AppTec Corporate Venture. The company has a team of experienced scientists, engineers, executives and advisors with entrepreneurial spirit to pioneer innovative technology and product development. Adagene is committed to building the fully integrated antibody technology as the innovation engine for generating superior antibodies to serve the needs for therapeutic antibodies with $60 billion sale in 2011.
天演药业由享誉全球的风险投资家、创业家、科学家、工程师及资深科学，法律及商业顾问组成。公司是由两位成功的生物医药企业家携手创办：创始人兼总裁罗培志博士曾任美国默克全资子公司抗体优化公司(Abmaxis)的共同创始人及首席技术官，兼默克公司(Merck & CO)生物制药研发部门主任；共同创始人李革博士是纽约上市公司--药明康德新药开发有限公司 (Wuxi AppTec)的创始人、董事长兼总裁。 天演药业由全球最大的投资管理集团富达风险基金─美国富达生物科技(Fidelity Bioscience)、富达国际风险投资(Fidelity Growth Partners Asia)和药明康德风险基金（Wuxi AppTec Venture）共同投资。
公司核心团队深厚的基础研究功底，精益求精的工作态度和强烈的创新意识，为技术和产品原创性提供根本的保证。 创业团队丰富的第一手实践经验及锐意进取的创业精神为公司的成长提供持续不断的动力。
天演药业将以其核心技术为动力，推动上游和下游的抗体技术之间的无缝整合， 为快速增长的治疗及诊断用抗体市场提供优质的产品及技术服务。 公司将开发针对恶性肿瘤的靶向治疗及诊断用抗体，并进一步扩展至针对重大疾病的抗体产品线。
公司简介（英）：
Adagene is an emerging biopharmaceutical company focused on developing novel technology based on computational biology and genetic engineering for generation and engineering of premier antibodies tailored to diagnostic and therapeutic application. The unique combination of the cutting edge informational technology and biotechnology for antibody engineering has positioned Adagene in the very front of the next generation of antibody technology for unmet biomedical needs in research, diagnostic and therapeutic applications. We are looking for self-motivated, ambitious engineers and scientists with solid training in IT and BT to develop your careers with us in a dynamic and fast-paced startup company.
Adagene is founded by two successful entrepreneurs in biopharmaceutical industry, Dr. Peter PeizhiLuo, Chairman and CEO of Adagene, who was the former director of biologics at Merck & Co., and Cofounder & Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co;and Dr. Ge Li, the founder, Chairman and CEO of WuXiAppTec Co., Ltd., a NYSE-listed global biopharmaceutical company. Adagene is backed by leading life science investors in US and Asia: Fidelity Bioscience in Boston, Fidelity Growth Fund, and Wuxi AppTec Corporate Venture. The company has a team of experienced scientists, engineers, executives and advisors with entrepreneurial spirit to pioneer innovative technology and product development. Adagene is committed to building the fully integrated antibody technology as the innovation engine for generating superior antibodies to serve the needs for therapeutic antibodies with $60 billion sale in 2011.